Automating the referral pathways for Multiple Myeloma through a Web Application and XMDD
DOI:
https://doi.org/10.14279/tuj.eceasst.81.1200Abstract
Multiple Myeloma (MM), a type of bone marrow cancer, is diagnosed by measuring monoclonal proteins, paraproteins (PP), and serum-free light chains (SFLC) in the blood. These proteins can be detected in healthy individuals at a lower level. This condition is called Monoclonal Gammopathy of Uncertain Significance (MGUS). MGUS is associated with a risk of progression to MM at a rate of 1-2% per year. Early diagnosis of MM correlates with improved overall survival for patients, so early referral of suspect cases is important. Two risk factors determine the risk of progression: a high-level PP (>15g/l) and an abnormal SFLC ratio. This risk stratification process enables General Practitioners (essentially, the family doctors) to manage the patients with low-risk MGUS and provides clear referral pathways for intermediate and high-risk MGUS patients. There are a reference algorithm and a scoring system for patient referrals with possible Multiple Myeloma, that in the current practice are processed manually by trained healthcare staff. In collaboration with the Haematology experts at the University Hospital Limerick and the SCCE group in Computer Science, we designed and implemented a software application that improves and streamlines the current process. This (online) application is developed with modern XMDD technology, using the DIME low-code application development tool. The application faithfully maps the reference algorithm in an automated way and applies it to a consultation data-set. The novelty consists in the adopted technologies, that improve the early validation and correctness of the software, and ease the human understanding and the modification turnaround of the application.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Electronic Communications of the EASST
This work is licensed under a Creative Commons Attribution 4.0 International License.